Marinus Pharmaceuticals (MRNS) Trading Up 5.3%

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were up 5.3% during trading on Wednesday . The company traded as high as $6.17 and last traded at $6.14. Approximately 736,407 shares changed hands during trading, a decline of 23% from the average daily volume of 956,239 shares. The stock had previously closed at $5.83.

A number of analysts have commented on MRNS shares. Mizuho started coverage on shares of Marinus Pharmaceuticals in a research note on Monday, March 19th. They set a “buy” rating and a $13.00 price objective for the company. HC Wainwright started coverage on shares of Marinus Pharmaceuticals in a research note on Thursday, February 15th. They set a “buy” rating and a $33.00 price objective for the company. Robert W. Baird started coverage on shares of Marinus Pharmaceuticals in a research note on Wednesday, May 23rd. They set an “outperform” rating and a $15.00 price objective for the company. Finally, ValuEngine raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Marinus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $18.00.

Get Marinus Pharmaceuticals alerts:

The stock has a market capitalization of $248.80 million, a PE ratio of -8.05 and a beta of 2.60.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. research analysts predict that Marinus Pharmaceuticals, Inc. will post -0.58 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of MRNS. Wells Fargo & Company MN purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $225,000. Barclays PLC purchased a new stake in shares of Marinus Pharmaceuticals in the first quarter worth approximately $232,000. Bank of New York Mellon Corp lifted its position in shares of Marinus Pharmaceuticals by 52.0% in the fourth quarter. Bank of New York Mellon Corp now owns 33,209 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 11,367 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $305,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $308,000. 55.21% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Leave a Reply

Your email address will not be published. Required fields are marked *